Research
Hormonal
Shorter telomeres in tumor tissue (breast, colon, prostate) are associated with advanced disease state, faster progression, and poorer survival, whereas leukocyte telomere length (LTL) shows inconsistent associations with cancer risk.
If you have cancer, shorter telomeres in the tumor tissue often signal a more aggressive disease. However, a blood test for telomere length (LTL) is not yet a reliable way to predict if you will get cancer, as research findings are inconsistent. Focus on proven risk reduction strategies rather than LTL testing for cancer prediction.
ModerateQualifiesMEDIUM confidence
There is good evidence that a reduced telomere length in cancer tissue from breast colon and prostate is associated with an advanced disease state at diagnosis, faster disease progression and poorer survival... However, the results of prospective studies [on LTL] are inconsistent.
Why this rating
Strong evidence for tumor tissue correlation, but conflicting evidence for LTL as a surrogate marker.
Source
Telomere biology and age-related diseases
Markus Herrmann et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2018
DOI 10.1515/cclm-2017-0870
narrative_reviewCited 189×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Shorter leukocyte telomere length (LTL) is associated with a significantly higher risk of all-cause mortality and cardiovascular disease (CVD).Good
- Lifestyle factors including regular physical activity, healthy diet (rich in vitamins/antioxidants), lower BMI, and no smoking are associated with longer telomeres and slower telomere shortening.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →